Clinical overview
The puerperium is one of the most consequential — and most missed — opportunities in a woman's reproductive life. A woman who leaves the postnatal ward without a contraceptive plan is at real risk of a short inter-pregnancy interval, and the data are unforgiving: pregnancies conceived within six months of a birth carry higher rates of preterm birth, low birthweight, uterine rupture in those with a previous caesarean (relevant to vbac), and maternal anaemia. The World Health Organization recommends spacing of at least 24 months from a live birth to the next conception. In South Africa, where the maternal mortality burden is driven by obstetric haemorrhage, hypertension and non-pregnancy-related infection (predominantly HIV) as documented in successive Saving Mothers reports, every avoided unintended pregnancy is a directly preventable risk exposure.
To evaluate postpartum contraceptive options is to weigh four variables simultaneously for each individual woman: (1) the timing since delivery and its effect on venous thromboembolism (VTE) and lactation; (2) breastfeeding status, because oestrogen-containing methods interact with both VTE risk and milk supply; (3) comorbidity, especially the obstetric complication that brought her to a high-risk delivery (pre-eclampsia, peripartum cardiomyopathy, prior VTE, previous caesarean); and (4) HIV status and antiretroviral therapy, which in the South African context is near-universal to consider. The single most effective intervention is to provide the chosen method before discharge — immediate postpartum long-acting reversible contraception (LARC) removes the access barrier that otherwise leaves women unprotected through the fertile window that reopens at around three weeks in the non-breastfeeding woman.
Core knowledge
Return of fertility and the lactational window
Ovulation can resume from approximately day 21–28 postpartum in a woman who is not breastfeeding; the first ovulation may precede the first menses, so a woman is fertile before she has any warning. Contraception is therefore advised from day 21 in the non-breastfeeder. In the fully breastfeeding woman, lactational amenorrhoea suppresses ovulation through prolactin-mediated inhibition of GnRH pulsatility.
The Lactational Amenorrhoea Method (LAM) is a legitimate, evidence-based method but is only reliable when all three conditions hold: the woman is fully or nearly fully breastfeeding, she remains amenorrhoeic, and the infant is under six months old. When all three are met, efficacy is high (standard teaching ~98% in the first six months). The moment any one condition fails — supplementary feeds begin, menses return, or six months pass — protection is lost and a transition method must already be in place. LAM should be taught as a bridge, never a destination.
Method classes
| Class | Examples (SA EML/national availability) | Oestrogen? | LARC? |
|---|---|---|---|
| Progestogen-only pill (POP) | Levonorgestrel/norethisterone POP; desogestrel POP | No | No |
| Injectable progestogen | DMPA (depot medroxyprogesterone acetate) IM; NET-EN | No | No |
| Implant | Etonogestrel subdermal implant | No | Yes |
| Levonorgestrel IUS | LNG-IUS | No | Yes |
| Copper IUD (Cu-IUD) | Copper intrauterine device | No | Yes |
| Combined hormonal contraception (CHC) | Combined oral pill, patch, ring | Yes | No |
| Permanent | Tubal ligation/occlusion; vasectomy (partner) | No | Permanent |
The conceptual division that matters most for postpartum evaluation is oestrogen-containing (CHC) versus progestogen-only/non-hormonal. Oestrogen is the problematic ingredient in the puerperium: it independently raises VTE risk during the already-prothrombotic postpartum period and can theoretically reduce milk volume in early lactation.
The two eligibility frameworks
Evaluation is anchored to medical eligibility criteria, which classify a method–condition pairing as Category 1 (no restriction), 2 (benefits generally outweigh risks), 3 (risks generally outweigh benefits — use only if better options unavailable, with expert judgement) or 4 (unacceptable health risk).
- The WHO Medical Eligibility Criteria for Contraceptive Use, 6th edition (2025) is the current international standard.
- South Africa's own National Contraception Clinical Guidelines (2019) and the Handbook for Contraceptive Method Provision (2019) remain the national documents, but they are aligned to the older WHO MEC 5th edition (2015). Where the SA guidance and WHO MEC 6th diverge — most importantly around HIV risk and antiretroviral interactions, which WHO has liberalised — flag the discrepancy and default to the more current evidence while remaining mindful of the operative national policy.
Timing categories the candidate must hold
The MEC timing framework for postpartum initiation:
- CHC: contraindicated in the first weeks because of VTE. Standard teaching, consistent with WHO MEC, is Category 4 (<6 weeks) in breastfeeding women, and Category 3 then 2 as time passes; in non-breastfeeding women, CHC is restricted in the first ~21 days because of VTE alone, then becomes more permissive once additional VTE risk factors (such as immobility, transfusion at delivery, BMI ≥30, smoking, pre-eclampsia) are excluded.
- Progestogen-only methods (POP, DMPA, implant): generally Category 1–2 and can be started immediately postpartum, including in breastfeeders. WHO MEC 6th treats the postpartum breastfeeding progestogen-only initiation more permissively than older editions.
- Intrauterine methods (Cu-IUD and LNG-IUS): Category 1 if inserted within 48 hours of delivery, or after 4 weeks. The interval 48 hours to 4 weeks is Category 3 because expulsion and perforation risk rise. Puerperal sepsis is Category 4 for IUD insertion.
Figure J5.1 — Postpartum timing clock for fertility return, LAM limits, CHC caution and IUD insertion windows.
Assessment
Evaluating the right method is a structured clinical judgement, not a menu hand-out. Work through a reproducible sequence.
History — the decision-driving questions
- What does she want, and how soon might she want another pregnancy? Desired family completeness reframes everything: a woman who is certain she is finished is a candidate for permanent methods or long-interval LARC; a woman spacing wants reversibility.
- Is she breastfeeding, and how exclusively? This sets the CHC and LAM calculus.
- The index pregnancy complication. A delivery complicated by severe pre-eclampsia, peripartum cardiomyopathy, prior or current VTE, or significant haemorrhage requiring transfusion changes the VTE and cardiovascular weighting against oestrogen. Cross-reference the woman's course in pre-eclampsia-and-hellp and hypertension-in-pregnancy.
- Mode of delivery and uterine integrity. A previous caesarean makes a short inter-pregnancy interval genuinely dangerous (uterine rupture risk in a future labour — see uterine-rupture and vbac); this strengthens the case for the most effective, longest-acting method.
- VTE risk factors: previous VTE, thrombophilia, BMI ≥30, immobility, smoking ≥35 years, family history.
- HIV status, ART regimen, and risk of acquisition. Document the regimen — South African first-line is TLD (tenofovir + lamivudine + dolutegravir) per the NDoH National Consolidated Guidelines (2026). Dolutegravir does not have the contraceptive-efficacy-lowering enzyme-induction problem that older efavirenz-based regimens raised, but always check current interaction guidance.
- Sepsis screen. Any suspicion of chorioamnionitis or puerperal sepsis is a hard stop for immediate IUD insertion.
Examination and investigations
- Blood pressure: a residually hypertensive postpartum woman has CHC pushed up the category scale.
- Signs of sepsis: temperature, uterine tenderness, offensive lochia — relevant to both IUD insertion and the differential of puerperal-complications.
- No routine investigation gates contraceptive provision. Pelvic examination, cervical screening, and laboratory tests are not prerequisites and must never be used to delay a method — a delay is itself a failure of care. The exception is targeted assessment driven by the history (e.g. confirming sepsis is excluded before IUD insertion). South African cervical screening proceeds on its own schedule per cervical-screening-sa and is not a barrier to contraception.
Weighing effectiveness against the woman's life
The HOTS task is to integrate typical-use effectiveness with the woman's circumstances. LARC methods (implant, LNG-IUS, Cu-IUD) have typical-use failure rates under 1% per year because they are not user-dependent. DMPA and the POP have meaningfully higher typical-use failure (the POP especially, being time-sensitive). A spacing decision for a woman with a previous caesarean and limited clinic access should weight a forgettable, highly effective LARC over a daily pill she may not be able to refill.
Management
The default offer: immediate postpartum LARC
The strongest evidence-based, access-protective action is to offer a LARC method before discharge.
- Immediate postpartum implant: the etonogestrel subdermal implant can be inserted on the postnatal ward in any woman regardless of breastfeeding status (progestogen-only, Category 1–2). It is the single most pragmatic "leave-no-woman-unprotected" intervention and is strongly supported in the South African contraception programme.
- Immediate postpartum IUD (PPIUD): insert the Cu-IUD or LNG-IUS within 48 hours of delivery (Category 1 in that window) — either at caesarean (intra-caesarean placement) or post-vaginal birth by a trained provider. After 48 hours, defer to ≥4 weeks because the 48-hour-to-4-week window is Category 3 for expulsion. Expulsion rates are higher than with interval insertion and the woman must be counselled to check threads and to return if she cannot feel them; even so, the effectiveness gain from not losing her to follow-up usually dominates.
If LARC is declined or unavailable
- DMPA injectable is the workhorse of the South African public sector — three-monthly, no oestrogen, immediately initiable postpartum including in breastfeeders. WHO MEC 6th edition explicitly rates DMPA Category 1 for women at high risk of HIV following the ECHO trial, settling earlier concern. Counsel about delayed return of fertility (which can take many months after the last injection) and reversible bone-density effects.
- POP: progestogen-only, no oestrogen, safe in breastfeeding, started immediately. Its weakness is adherence — emphasise the daily, time-sensitive nature.
- CHC: defer in line with MEC timing. In a breastfeeding woman avoid CHC in the first 6 weeks (Category 4) and weigh it cautiously thereafter; in a non-breastfeeding woman with no other VTE risk factors, CHC may be considered from about 3 weeks, but only after the puerperal VTE window and any delivery-related risk factors are accounted for. CHC is rarely the right first answer postpartum.
Permanent methods
For the woman whose family is complete, discuss tubal ligation/occlusion (and partner vasectomy as the lower-risk alternative). Postpartum tubal ligation, including at the time of caesarean, is convenient but the counselling must be unhurried and the consent free of coercion. Consent for sterilisation obtained in labour or under the duress of an acute delivery is ethically and legally fraught — South African law and good practice require capacitated, informed, voluntary consent; sterilisation is regulated, and historic abuses make scrupulous consent non-negotiable (see sa-og-law and informed-consent). Where there is any doubt about the durability of the decision, offer interval LARC now and a planned interval sterilisation later.
Emergency contraception and the missed window
If a postpartum woman presents having resumed intercourse without protection beyond the lactational window, emergency contraception is appropriate. The copper IUD is the most effective emergency contraceptive and conveniently transitions to ongoing LARC; oral emergency options (levonorgestrel; ulipristal acetate where available) are alternatives. Use the encounter to start an ongoing method the same day ("quick start").
A clear postnatal-ward drill
Make the pathway unmistakable so no woman is discharged unprotected:
- Counsel antenatally — the contraceptive conversation belongs at booking and in the third trimester, not at discharge (antenatal-booking).
- At delivery, if implant or PPIUD is chosen and there is no sepsis, place it within the appropriate window (implant any time; IUD within 48 h).
- Before discharge, every woman has a documented method in place or scheduled, with the bridging plan (LAM limits, POP/DMPA start date) written down.
- HIV-positive women continue ART; dual protection with condoms is advised for HIV/STI prevention alongside the chosen contraceptive (hiv-counselling).
- Book the postnatal visit (around 3–6 days and 6 weeks per the SA Maternity Guideline) to reinforce and, where deferred, to initiate IUD/CHC.
Figure J5.2 — Postnatal-ward drill for leaving every woman with a method in place or a booked bridge.
Red flags / pitfalls
- Discharging without a plan. The commonest and most damaging error. Fertility returns before the 6-week visit; "we'll sort it at six weeks" leaves a fertile window unprotected.
- Giving CHC too early or in the wrong woman. Oestrogen in the early puerperium — especially in a breastfeeding woman within 6 weeks, or any woman with unresolved pre-eclampsia, prior VTE, or immobility — is a real harm, not a paperwork category. Reach for progestogen-only or non-hormonal first.
- Inserting an IUD in the 48-hour-to-4-week window electively — this is the Category-3 expulsion/perforation window. Insert within 48 hours or wait to ≥4 weeks.
- Any IUD insertion in suspected puerperal sepsis — Category 4. Treat the sepsis (puerperal-complications); do not introduce an intrauterine foreign body into an infected uterus.
- Over-relying on LAM. It fails the instant exclusivity, amenorrhoea, or the six-month limit is breached. Always pair it with a ready transition method.
- Coerced or labour-ward sterilisation consent. Never accept sterilisation consent taken under acute duress; this is an ethical and legal trap (informed-consent).
- Using investigations as a barrier. Withholding a method pending an examination, smear, or blood test that the history does not require is a missed-opportunity failure.
- Forgetting the previous caesarean. A short interval after caesarean materially raises future uterine-rupture risk; this woman needs the most reliable method, not the most convenient one for the clinic.
- Treating HIV as a contraindication. It is not. DMPA is Category 1 even at high HIV-acquisition risk; the real task is dual protection and ART-interaction awareness, not method denial.
Figure J5.3 — Exam-risk filters that push postpartum contraception toward safer non-oestrogen or LARC choices.
Evidence anchors
- WHO Medical Eligibility Criteria for Contraceptive Use, 6th edition (2025) — current international standard for method–condition categories, postpartum timing, and the DMPA Category-1-at-high-HIV-risk position. Note: the precise category for a given condition–timing pair should be confirmed against the current MEC wheel before clinical use.
- South African National Contraception Clinical Guidelines (2019) and the South African Handbook for Contraceptive Method Provision (2019), NDoH — the operative national documents, aligned to WHO MEC 5th edition (2015); flag divergence from MEC 6th, especially on HIV/ARV.
- FSRH (UK) UK Medical Eligibility Criteria (UKMEC 2016, amended 2019) + method-specific FSRH guidance — useful cross-reference for postpartum and breastfeeding categories.
- National Integrated Maternal and Perinatal Care Guideline (NDoH, 2024), NDoH — postnatal visit schedule and the antenatal-to-discharge contraceptive counselling pathway.
- National Consolidated Guidelines for the Prevention and Management of HIV (NDoH, published January 2026) — supersedes the 2023 ART + 2019 PMTCT guidelines; TLD first-line; ART–contraceptive interaction context.
- Saving Mothers Report (NCCEMD) — the SA maternal-mortality drivers (obstetric haemorrhage, hypertension, HIV-related infection) that make inter-pregnancy spacing a direct safety intervention.
- Choice on Termination of Pregnancy Act 92 of 1996 and the Sterilisation Act 44 of 1998 — context for the consequences of unmet contraceptive need and for permanent-method consent standards.